IL153879A0 - Modified virus - Google Patents

Modified virus

Info

Publication number
IL153879A0
IL153879A0 IL15387901A IL15387901A IL153879A0 IL 153879 A0 IL153879 A0 IL 153879A0 IL 15387901 A IL15387901 A IL 15387901A IL 15387901 A IL15387901 A IL 15387901A IL 153879 A0 IL153879 A0 IL 153879A0
Authority
IL
Israel
Prior art keywords
modified virus
virus
modified
Prior art date
Application number
IL15387901A
Other languages
English (en)
Original Assignee
Got A Gene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Got A Gene Ab filed Critical Got A Gene Ab
Publication of IL153879A0 publication Critical patent/IL153879A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/55—Vectors comprising as targeting moiety peptide derived from defined protein from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15387901A 2000-07-19 2001-07-19 Modified virus IL153879A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0017720.4A GB0017720D0 (en) 2000-07-19 2000-07-19 Modified virus
PCT/GB2001/003252 WO2002008263A2 (en) 2000-07-19 2001-07-19 Modified virus having an altered tropism

Publications (1)

Publication Number Publication Date
IL153879A0 true IL153879A0 (en) 2003-07-31

Family

ID=9895953

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15387901A IL153879A0 (en) 2000-07-19 2001-07-19 Modified virus

Country Status (15)

Country Link
US (1) US7456008B2 (cs)
EP (1) EP1301613A2 (cs)
JP (1) JP2004504062A (cs)
CN (1) CN1443243A (cs)
AU (2) AU7087901A (cs)
BR (1) BR0112624A (cs)
CA (1) CA2413851A1 (cs)
CZ (1) CZ2003152A3 (cs)
GB (1) GB0017720D0 (cs)
IL (1) IL153879A0 (cs)
MX (1) MXPA03000449A (cs)
NO (1) NO20030239L (cs)
NZ (1) NZ524251A (cs)
PL (1) PL360350A1 (cs)
WO (1) WO2002008263A2 (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002063010A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Method of producing recombinant antibodies against tumors
US20040077081A1 (en) 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
EP1524995B1 (en) 2002-07-01 2011-12-21 Wilex AG Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
SE0301936D0 (sv) * 2003-06-30 2003-06-30 Affibody Ab New polypeptide
CA2531238C (en) * 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
SE0301987D0 (sv) * 2003-07-04 2003-07-04 Affibody Ab New polypeptide
US20070275873A1 (en) * 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
EP1842548A4 (en) * 2004-11-30 2010-01-06 Kiim Pharm Lab Inc ANTI-HIV MEDIUM, THIS PRESENT POLYPEPTIDE, POLYPEPTIDE ENCODING GENE AND PROCESS FOR PREPARING THE ANTI-HIV MEDIUM
EP1885867B1 (en) * 2005-05-20 2011-12-28 GlaxoSmithKline LLC Novel methods
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
EP3072900A1 (en) 2015-03-27 2016-09-28 Medizinische Hochschule Hannover Anti-tumour medicament based on adenovirus
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
KR20200140848A (ko) 2018-04-09 2020-12-16 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 복제 속성이 향상된 종양살상형 아데노바이러스 조성물
CN110590939B (zh) * 2019-09-20 2024-02-02 广州暨南大学医药生物技术研究开发中心有限公司 一种利用基因工程获得重组人纤连蛋白的方法
WO2021087019A1 (en) * 2019-11-01 2021-05-06 University Of Houston System Oncolytic virotherapy with induced anti-tumor immunity
CN116334010B (zh) * 2023-05-30 2023-08-29 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
EP0863987B1 (en) * 1995-11-28 2008-01-02 Genvec, Inc. Vectors and methods for gene transfer to cells
HUP0002070A2 (hu) 1997-05-28 2000-10-28 Genvec, Inc. Alternatív módon célba juttatott adenovírus
CA2321135A1 (en) 1998-02-17 1999-08-19 Uab Research Foundation Modified adenovirus containing a fiber replacement protein
KR20020013464A (ko) 1998-08-27 2002-02-20 추후제출 이종 유전자의 전달을 위한 표적화된 아데노바이러스 벡터
AU767975B2 (en) * 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
CN1359391A (zh) * 1999-07-06 2002-07-17 哥德－A－基因股份公司 重组腺病毒

Also Published As

Publication number Publication date
NO20030239D0 (no) 2003-01-17
BR0112624A (pt) 2003-07-01
CZ2003152A3 (cs) 2003-05-14
MXPA03000449A (es) 2004-12-13
AU2001270879B2 (en) 2007-09-20
PL360350A1 (en) 2004-09-06
WO2002008263A3 (en) 2002-06-13
EP1301613A2 (en) 2003-04-16
CA2413851A1 (en) 2002-01-31
US20040132007A1 (en) 2004-07-08
JP2004504062A (ja) 2004-02-12
CN1443243A (zh) 2003-09-17
US7456008B2 (en) 2008-11-25
WO2002008263A2 (en) 2002-01-31
AU7087901A (en) 2002-02-05
GB0017720D0 (en) 2000-09-06
NO20030239L (no) 2003-03-18
NZ524251A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
GB2368233B (en) Maintaining virus detection software
DE50104081D1 (en) Hydrolager
AU3391801A (en) Pyridinylimidazoles
AU8274301A (en) Electro-powder
DE50105205D1 (en) Creatinin-biosensor
GB0017720D0 (en) Modified virus
GB0024200D0 (en) Component vaccine
AU6803901A (en) Bis-arylsulfones
DE50102859D1 (en) Hochfliessfähige propylenblockcopolymerisate
AU9385201A (en) Sulfonylguanidine
DE50008626D1 (en) Substituierte aminomethyl-phenyl-cyclohexanderivate
AU6619001A (en) Liquid-pourers
DE50008447D1 (en) Aminomethyl-phenyl-cyclohexanonderivate
GB0001475D0 (en) Virus strains
AU4686401A (en) Hypotensors
AU9187601A (en) Triazolo-epothilones
DE50100877D1 (en) Thermoverformbares verbundmaterial
GB0028849D0 (en) Improved keysheath
DE50006446D1 (en) Otoplastik
AU4831301A (en) Gm-negative ehv-mutants
AU8756801A (en) Thienopyrrolidinones
DE50013705D1 (en) Otoplastik
DE50103809D1 (en) Hydrocephalusventil
DE50003404D1 (en) Multi-master-bus-system
GB0027433D0 (en) Vaccine component